

VIVALDIS V  
Animal Health

# PetSmile

EDITION-158



## FIRST TREATMENT FOR DELAYING CANINE CONGESTIVE HEART FAILURE RECEIVES FDA APPROVAL

The U.S. Food and Drug Administration (FDA) has approved an expanded indication for pimobendan (Vetmedin)—in both chewable tablet and oral solution forms—to delay the onset of congestive heart failure (CHF) in dogs with stage B2 preclinical myxomatous mitral valve disease (MMVD), making it the first and only FDA-approved treatment for this early stage of canine heart disease. This full approval builds on a conditional approval granted in 2022 and is supported by multisite studies showing that dogs treated with pimobendan experienced significantly delayed progression to CHF and extended symptom-free survival compared with untreated dogs. The expanded label also maintains its longstanding use for managing mild to severe CHF due to MMVD or dilated cardiomyopathy, and the drug's safety profile and potential side effects—such as lethargy, poor appetite, and gastrointestinal upset—have been documented in field studies. Heart disease affects about 10 % of dogs in their lifetime, with MMVD representing the majority of cases, particularly in smaller breeds, and early treatment with pimobendan may improve both survival time and quality of life.



### PIMOBEN

3 x 10 tablets



### PIMOBEN - Solo


3 x 10 tablets

## BREAKING THE ITCH-SCRATCH CYCLE— ONCE DAILY WITH ILUNOCITINIB TABLETS

Ilunocitinib is a once-daily oral medication approved by the U.S. Food and Drug Administration (FDA) for the control of pruritus (itching) associated with allergic dermatitis and for managing atopic dermatitis in dogs aged 12 months and older. It belongs to the Janus Kinase (JAK) inhibitor class and works by blocking the immune signaling pathways that trigger itch and inflammation, helping break the itch-scratch cycle and improve skin condition. Clinical studies have shown it to be at least as effective as existing JAK inhibitor options, with convenient once-daily dosing and without the need for loading or tapering. It includes a boxed warning about the potential for inadequate immune response to vaccines, requiring treatment to be withheld before and after vaccination, and it may increase susceptibility to infections; common observed side effects include vomiting, diarrhea, and lethargy. It is indicated only for dogs (not cats), and veterinarians should assess risks and benefits for each patient.

### PRURIGO

50 ml



### Oclapet

10 x 1 x 10 tablets



## A NEW ERA IN LONG-LASTING RELIEF FOR CANINE OSTEOARTHRITIS PAIN

A long-acting injectable therapy for dogs with osteoarthritis has received European marketing authorization, marking a significant advance in chronic pain management. This novel treatment works by targeting nerve growth factor (NGF), a key driver of osteoarthritis pain, and has been shown to provide effective pain relief and improved mobility for up to three months with a single injection. Clinical studies demonstrated meaningful improvements in comfort and movement, offering veterinarians a valuable option for dogs that may not tolerate or respond well to daily oral medications. This approval highlights the growing role of biologic therapies in veterinary medicine and their potential to enhance long-term quality of life for dogs living with osteoarthritis.



**FIROtail**

10 x 1 x 6

**GRAPITAIL**

10 x 1 x 6



# VIVALDIS EVENTS

In January 2026, we actively participated in and supported multiple prestigious veterinary events across India, reinforcing our commitment to clinical education and engagement with the veterinary community. Our presence spanned the International Veterinary Conference & Expo in Mumbai (10–11 Jan), Vetexcellence 2026 in Greater Noida (10–12 Jan), the PPAM CE on Exotic Animal Treatment and Surgery at Mumbai Zoo, and a dedicated Vivaldis Renal CE Programme in Kochi, Kerala. Across these platforms, we connected with 600+ veterinarians, showcased our key innovations including Reno-Nex, Vetecto, Oclapet, and Cat Diets, and facilitated meaningful discussions on diverse topics such as critical cytology, pet nutrition, endocrine disorders, reproductive challenges, exotic animal treatment, and chronic kidney disease management. These engagements, enriched by renowned national and international speakers, reflected our continued focus on advancing scientific knowledge, supporting clinical excellence, and strengthening partnerships within the veterinary fraternity.

- International Veterinary Conference & Expo, Mumbai by the VPWA
- Vetexcellence 2026, organized by the PPA
- PPAM CE on Exotic Animal Treatment Mumbai
- Vivaldis Renal CE Programme, Kochi, Kerala
- PetFed Bangalore

